Healthcare
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.
Tan Tock Seng Hospital and Lucence are developing a next generation decision support tool for liver cancer patients, which aims to reduce the risks associated with liver cancer surgery.
Cerecin continues to strengthen its experienced team in Asia Pacific as it accelerates clinical development plans
Seven proton therapy rooms already sold by IBA this year
Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences
Cancer cells appear to adapt to treatment with checkpoint blocker drugs by altering a metabolic process, leading to shorter survival for patients
US FDA 510(k) clearance paves the way for an innovative orthopedic product that offers the potential to improve bone apposition and, as a consequence, patient outcomes 1-3
OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment
GE Healthcare is partnering with multiple companies and academic institutions to develop a portfolio of targeted Positron Emission Tomography (PET) tracers to better predict and monitor patient response to immunotherapies.
PRESS RELEASES